生物制药公司Lipocine Inc宣布,其用于治疗产后抑郁症(PPD)的在研药物LPCN 1154,其关键性第三阶段临床试验已完成最后一例患者的最终访视。这一重要里程碑标志着该试验患者参与阶段已顺利结束,公司下一步将进行数据整理与分析,为后续向监管机构提交申请奠定基础。
生物制药公司Lipocine Inc宣布,其用于治疗产后抑郁症(PPD)的在研药物LPCN 1154,其关键性第三阶段临床试验已完成最后一例患者的最终访视。这一重要里程碑标志着该试验患者参与阶段已顺利结束,公司下一步将进行数据整理与分析,为后续向监管机构提交申请奠定基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.